Compare RELY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | SUPN |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2021 | 2010 |
| Metric | RELY | SUPN |
|---|---|---|
| Price | $16.75 | $55.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $24.13 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 4.5M | 783.2K |
| Earning Date | 05-20-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 263.16 | ★ 6500.00 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | $392,755,000.00 |
| Revenue This Year | $19.99 | $8.18 |
| Revenue Next Year | $18.40 | $22.15 |
| P/E Ratio | $52.42 | ★ N/A |
| Revenue Growth | ★ 29.37 | N/A |
| 52 Week Low | $12.08 | $29.16 |
| 52 Week High | $24.63 | $59.68 |
| Indicator | RELY | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 69.58 |
| Support Level | $15.17 | $47.95 |
| Resistance Level | $17.39 | $57.65 |
| Average True Range (ATR) | 0.76 | 2.03 |
| MACD | 0.38 | 0.57 |
| Stochastic Oscillator | 78.79 | 63.80 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.